HER2-positive colorectal cancer

HER2-positive colorectal cancer is a distinct molecular subtype of lower gastrointestinal adenocarcinoma characterized by the amplification of the *ERBB2* gene, overexpression of the human epidermal growth factor receptor 2 protein, or both Occurring in approximately 2% to 5% of all colorectal malignancies—and more frequently identified in distal, left-sided, and *RAS*/*BRAF* wild-type tumors—it drives unchecked cell proliferation and survival via hyperactivation of downstream MAPK and PI3K/Akt ...

HER2-positive colorectal cancer is a distinct molecular subtype of lower gastrointestinal adenocarcinoma characterized by the amplification of the *ERBB2* gene, overexpression of the human epidermal growth factor receptor 2 protein, or both Occurring in approximately 2% to 5% of all colorectal malignancies—and more frequently identified in distal, left-sided, and *RAS*/*BRAF* wild-type tumors—it drives unchecked cell proliferation and survival via hyperactivation of downstream MAPK and PI3K/Akt ...

HER2-positive colorectal cancer is a distinct molecular subtype of lower gastrointestinal adenocarcinoma characterized by the amplification of the *ERBB2* gene, overexpression of the human epidermal growth factor receptor 2 protein, or both

Occurring in approximately 2% to 5% of all colorectal malignancies—and more frequently identified in distal, left-sided, and *RAS*/*BRAF* wild-type tumors—it drives unchecked cell proliferation and survival via hyperactivation of downstream MAPK and PI3K/Akt signaling cascades

Clinically identified via immunohistochemistry and in situ hybridization assays, this biomarker status mediates primary resistance to standard anti-EGFR therapies and defines an actionable therapeutic target in advanced or metastatic disease

Clinically identified via immunohistochemistry and in situ hybridization assays, this biomarker status mediates primary resistance to standard anti-EGFR therapies and defines an actionable therapeutic target in advanced or metastatic disease